Peru has temporarily suspended clinical trials of the Covid vaccine developed by Chinese drug giant Sinopharm. This happened after authorities detected some neurological problems in one of its test volunteers thereby avoiding further damage.
According to local media, the volunteer had difficulty moving their arms and this prompted the National Institution of Health to interrupt the trials.
‘’Several days ago, we signaled, as we are required, to the regulatory authorities that one of our participants (in trials) presented neurological symptoms which could correspond to a condition called Guillian-Barre syndrome,’’ said chief researcher German Malaga to the press.
Guillian-Barre syndrome is a rare and non-contagious disorder which affects the movement of the arms and legs. Peru declared a temporary health emergency in five regions in June last year following multiple cases of the syndrome.
Peru’s clinical trials for the Sinopharm vaccine were due to conclude this week after testing around 12,000 people. However, the effectiveness of the vaccine will not be known until at least mid-2021 if it is even successful.
China expected the Peruvian Government to buy up to 20 million doses to inoculate two-thirds of its population.
Over 60,000 people across the globe have already taken the Sinopharm vaccine including volunteers from Argentina, Russia, and Saudi Arabia.
- Possible Allergic Reactions To COVID-19 Vaccine Prompts Investigations In UK
- Biden Promises 100 Million COVID Vaccines in First 100 Days
- New Hope: Uganda’s Covid 19 Vaccine Trials To Start in November
Please use the button below to contribute to Newslex Point, Inc. using a credit card or via PayPal.